Áttétes emlőrák: vizsgálatok itt: Hongkong
7 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peoplePhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Where
- Hong Kong
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00 - 3. fázisTaking peopleA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Where
- Hong Kong
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00 - 3. fázisTaking peopleSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Where
- Hong Kong
- Életkor
- 18 év and over
- People
- 788 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Where
- Hong Kong
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00 - 3. fázisTaking peopleA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Where
- Hksar, Shatin
- Életkor
- 18 év and over
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00 - 1. fázisTaking peoplePhase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- Where
- Hong Kong
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT06784193 - 3. fázisTaking peoplePalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Where
- Hong Kong
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00